A 25-year longitudinal analysis of treatment efficacy in inborn errors of metabolism. (Q53460357)

14 May 2018

title

A 25-year longitudinal analysis of treatment efficacy in inborn errors of metabolism. (English)

1 reference

14 May 2018

author

Philippe M. Campeau

series ordinal

1

1 reference

14 May 2018

John J. Mitchell

series ordinal

3

1 reference

14 May 2018

Charles R. Scriver

series ordinal

2

object named as

Charles R Scriver

0 references

publication date

12 August 2008

1 reference

14 May 2018

Molecular Genetics and Metabolism

published in

1 reference

14 May 2018

volume

95

1 reference

14 May 2018

issue

1-2

1 reference

14 May 2018

page(s)

11-16

1 reference

14 May 2018

Incidence of inborn errors of metabolism in British Columbia, 1969-1996.

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Inborn errors of metabolism in the Italian pediatric population: A national retrospective survey

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

The incidence of inherited metabolic disorders in the West Midlands, UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

The effect of Mendelian disease on human health. II: Response to treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

The effect of Mendelian disease on human health: a measurement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Disorders of carnitine transport and the carnitine cycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Hyperlysinemia without clinical findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Changing perspectives on the benefits of newborn screening

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Lumping and splitting: molecular biology in the genetics clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

On lumpers and splitters, or the nosology of genetic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

The variable presentations of glycogen storage disease type IV: a review of clinical, enzymatic and molecular studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

New frontiers in hereditary metabolic disease: an historical perspective.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Metabolomics identifies perturbations in human disorders of propionate metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

HMDB: the Human Metabolome Database

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Inborn errors of metabolism: the flux from Mendelian to complex diseases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Recommendations of the 2006 Human Variome Project meeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

The human disease network

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Maple syrup urine disease: favourable effect of early diagnosis by newborn screening on the neonatal course of the disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Newborn screening for glutaric aciduria type I in Victoria: treatment and outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Neonatal screening for citrullinaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Prevention of brain disease from severe 5,10-methylenetetrahydrofolate reductase deficiency.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Quantitative determination of guanidinoacetate and creatine in dried blood spot by flow injection analysis-electrospray tandem mass spectrometry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Combined liquid chromatography-tandem mass spectrometry as an analytical method for high throughput screening for X-linked adrenoleukodystrophy and other peroxisomal disorders: preliminary findings

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Retrospective determination of ceruloplasmin in newborn screening blood spots of patients with Wilson disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Use of serum on Guthrie cards in screening for congenital disorders of glycosylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Two-tiered universal newborn screening strategy for severe combined immunodeficiency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Newborn screening: After the thrill is gone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Newborn urine screening experience with over one million infants in the Quebec Network of Genetic Medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

The PAH gene, phenylketonuria, and a paradigm shift

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Influence of phenylalanine intake on phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Phenylketonuria: dietary and therapeutic challenges

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Double blind placebo control trial of large neutral amino acids in treatment of PKU: effect on blood phenylalanine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

A novel approach for enzyme replacement therapy. The use of phenylalanine hydroxylase-based fusion proteins for the treatment of phenylketonuria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Genetic medicines: treatment strategies for hereditary disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

Human monogenic disorders - a source of novel drug targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

A journey of hope: lessons learned from studies on rare diseases and orphan drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

National collaborative study groups: structure, benefits gained and potential for rare genetic diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2008.07.001

10.1016/J.YMGME.2008.07.001

7 January 2021

Identifiers

DOI

1 reference

14 May 2018

1 reference

14 May 2018